Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 12

Results For "Form-483"

120 News Found

US FDA Inspection at Alkem's Indore manufacturing facility
Drug Approval | July 08, 2022

US FDA Inspection at Alkem's Indore manufacturing facility

This GMP and Pre-Approval Inspection is part of the routine business operations and the company shall submit to US FDA within the stipulated timeline


Cipla updates on US FDA product-specific pre-approval inspection
News | July 06, 2022

Cipla updates on US FDA product-specific pre-approval inspection

The company has received 2 observations on FDA Form 483 with respect to ANDA filed for the product to be manufactured at Indore plant.


USFDA conducts inspection at Glenmark's Aurangabad manufacturing facility
News | July 04, 2022

USFDA conducts inspection at Glenmark's Aurangabad manufacturing facility

The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.


Glenmark Pharmaceuticals to address USFDA’s observation
News | June 23, 2022

Glenmark Pharmaceuticals to address USFDA’s observation

U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi


Briefs: Marksans Pharma and Alkem
News | June 22, 2022

Briefs: Marksans Pharma and Alkem

The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.


Glenmark Pharma gets observations from USFDA for its Goa and Monroe facilities
News | May 22, 2022

Glenmark Pharma gets observations from USFDA for its Goa and Monroe facilities

A total of five observations for Goa and 17 for Monroe


Aurobindo Pharma Ltd gets 6 observations from USFDA for Unit VII
News | May 11, 2022

Aurobindo Pharma Ltd gets 6 observations from USFDA for Unit VII

The unit is an oral manufacturing facility at Jedcherla, Hyderabad


Indian pharma companies must become the global benchmark of quality: Amit Jaju, Sr. MD, India, Ankura Consulting
interviews | March 13, 2022

Indian pharma companies must become the global benchmark of quality: Amit Jaju, Sr. MD, India, Ankura Consulting

Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements


Ankura launches pharmaceutical data integrity solution
News | March 08, 2022

Ankura launches pharmaceutical data integrity solution

Data integrity early warning system assists pharmaceutical clients in proactively identifying and managing data integrity challenges in line with regulatory guidelines


U.S. FDA completes inspection of Biocon Biologics, Malaysia with six observations
Biotech | September 26, 2021

U.S. FDA completes inspection of Biocon Biologics, Malaysia with six observations

The company does not expect the outcome of this inspection to impact its plans